- Buchbinder, David;
- Brazauskas, Ruta;
- Bo-Subait, Khalid;
- Ballen, Karen;
- Parsons, Susan;
- John, Tami;
- Hahn, Theresa;
- Sharma, Akshay;
- Steinberg, Amir;
- DSouza, Anita;
- Kumar, Anita;
- Yoshimi, Ayami;
- Wirk, Baldeep;
- Shaw, Bronwen;
- Freytes, César;
- LeMaistre, Charles;
- Bredeson, Christopher;
- Dandoy, Christopher;
- Almaguer, David;
- Marks, David;
- Szwajcer, David;
- Hale, Gregory;
- Schouten, Harry;
- Hashem, Hasan;
- Schoemans, Hélène;
- Murthy, Hemant;
- Lazarus, Hillard;
- Cerny, Jan;
- Tay, Jason;
- Yared, Jean;
- Adekola, Kehinde;
- Schultz, Kirk;
- Lehmann, Leslie;
- Burns, Linda;
- Aljurf, Mahmoud;
- Diaz, Miguel;
- Majhail, Navneet;
- Farhadfar, Nosha;
- Kamble, Rammurti;
- Olsson, Richard;
- Schears, Raquel;
- Seo, Sachiko;
- Beattie, Sara;
- Chhabra, Saurabh;
- Savani, Bipin;
- Badawy, Sherif;
- Ganguly, Siddhartha;
- Ciurea, Stefan;
- Marino, Susana;
- Gergis, Usama;
- Kuwatsuka, Yachiyo;
- Inamoto, Yoshihiro;
- Khera, Nandita;
- Hashmi, Shahrukh;
- Wood, William;
- Saber, Wael
Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.